Partners

European funding and a European consortium

InvestEU, the European Investment Fund, national development banks and the GATEWAY EUROSTARS 4 consortium.

Row of European Union flags (photo: Guillaume Périgois, Unsplash)

Partners & funding

Backed by EU instruments and a European consortium

This operation benefits from support from the European Union under the InvestEU Fund. Alongside seed equity, P3T stacks non-dilutive European funding — a capital-efficient path where milestones are de-risked by external review.

HBOR — Hrvatska banka za obnovu i razvitak

12259-GATEWAY · EUROSTARS 4 consortium (application pending)

P3 Therapeutics
Croatia
Coordinator
LBMC
Latvia
Ralf Bulks
Website
University of Latvia (LU)
Latvia
Una Rekstina, Vadims Parfejevs
Website
CubaseBio
Sweden
Malte Kuenemund, Julian Asbby
Website
Protavio
Greece
Exarchos Kanelis
Website
GrantMinded
Netherlands
Tom van Tilborg, Gido Akse — grant consultants
Website

EUROSTARS 4 application, project 12259-GATEWAY: “Gut-enthesis Axis Therapeutic Evaluation Workflow for multi-omics Analysis Yielding therapeutics and biomarkers” — a 2D and 3D humanised gut-entheseal organ-on-chip platform. If funded, it will be used to study mechanism of action (MoA), pharmacokinetics (PK) and pharmacodynamics (PD) of our SCMs, and for compound biomarker development.

Research and development partners

The contract research and technology partners behind the hit-to-lead candidate work: chemistry, ADME and PK prediction, liver-toxicity profiling and gut models.